Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411385 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
A Phase 3 study of Chronic Hepatitis C, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 933
- Enrollment target
- 20
- Study locations
NCT00411385: Completed Phase 3 study of Chronic Hepatitis C, sponsored by Human Genome Sciences.
NCT00411385 is a Phase 3 study of Chronic Hepatitis C that has completed, run by Human Genome Sciences. The registered enrollment target is 933 participants, above the 156-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (498% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00411385, a Phase 3 study of Chronic Hepatitis C, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 933 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who are IFNa treatment naive.
Conditions Studied
Interventions
- DRUG Ribavirin
- DRUG albumin interferon alfa-2b
- DRUG peginterferon alfa-2a
Study Locations (20)
Florida
- University of Florida-Gainesville - Gainesville
- Shands Jacksonville Medical Center - Jacksonville
- Mayo Clinic Transplant Center - Jacksonville
- University of Miami - Miami
New York
- New York Hospital - Cornell - New York
- Faculty Practice Associates - New York
- NY Presbyterian Medical Center - Columbia Univ. Med Center - New York
- Bronx VA Medical Center - The Bronx
California
- Scripps Clinic - La Jolla
- California Pacific Medical Center - San Francisco
Georgia
- Atlanta Gastroenterology Associates - Atlanta
- GI of Atlanta - Atlanta
Arizona
- Mayo Clinic Hospital - Phoenix
Colorado
- University of Colorado - Denver
Illinois
- University of Chicago Hospital - Chicago
Maryland
- Johns Hopkins Center for Viral Hepatits - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 933 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
What the finished NCT00411385 record still lists
NCT00411385 is an interventional study that assigns participants to a tested intervention. The registered 933 participants enrollment target is mid-sized for trials with a published cap, above the 156-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (498% higher).
The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Ribavirin is the first listed.
NCT00411385 names 20 study sites across 12 states, led by Florida, New York, California.
Frequently Asked Questions
What is clinical trial NCT00411385 about?
NCT00411385 is a clinical study titled "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3". This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who ...
What is the current status of trial NCT00411385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 933 participants. The study started on 2007-02. Estimated completion is 2008-10.
What conditions does trial NCT00411385 study?
This clinical trial studies the following conditions: Chronic Hepatitis C.
What interventions are being tested in trial NCT00411385?
The interventions under investigation include: Ribavirin (DRUG), albumin interferon alfa-2b (DRUG), peginterferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT00411385?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00411385 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00411385's enrollment target sits among peer trials
933 2nd of 16 the highest of 16 other Chronic Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
COMPLETED · Phase 3
-
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
COMPLETED · Phase 3
-
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
COMPLETED
-
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
COMPLETED · Phase 1
-
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
COMPLETED · Phase 2
-
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- NCT05519007 · 936 participants · NA
Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia